Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer

Byun,Jung  Mi; Jeong,Dae  Hoon; Lee,Dae  Sim; Kim,Joo  Ran; Park,Sae  Gwang; Kang,Mi  Seon; Kim,Young  Nam; Lee,Kyung  Bok; Sung,Moon  Su; Kim,Ki  Tae

doi:10.3892/or.2013.2243

Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer

Authors:
- Jung Mi Byun
- Dae Hoon Jeong
- Dae Sim Lee
- Joo Ran Kim
- Sae Gwang Park
- Mi Seon Kang
- Young Nam Kim
- Kyung Bok Lee
- Moon Su Sung
- Ki Tae Kim
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University, Busan 614-735, Republic of Korea, Department of Microbiology, Busan Paik Hospital, Inje University, Busan 614-735, Republic of Korea, Department of Pathology, Busan Paik Hospital, Inje University, Busan 614-735, Republic of Korea
Published online on: January 18, 2013 https://doi.org/10.3892/or.2013.2243
Pages: 1540-1546

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tetraarsenic oxide (As4O6, TAO) is a new arsenic compound that inhibits cell growth and induces apoptosis in human cervical cancer cell lines. In the present study, we report that the growth of tumor cells (CaSki) was inhibited by treatment with TAO alone or in combination with cisplatin or paclitaxel in vitro and in vivo. Proliferation was assessed by WST-1 assay, and apoptosis was assessed by Annexin-V/PI FACS analysis in the CaSki cell line treated with a single agent or with the combinations of two agents. Expression of apoptosis-related proteins was analyzed by western blot analysis. A mouse xenograft model using CaSki cells was used to determine the in vivo activity of tetraarsenic oxide alone and in combination with cisplatin or paclitaxel by estimation of tumor size. At the end of the experiment, tumor tissue from each mouse was removed and processed for TUNEL analysis for confirmation of apoptotic cells. TAO was able to inhibit cell proliferation in a time- and dose-dependent manner. A combination of TAO and cisplatin effectively induced apoptosis by activating caspase-3. Using a mouse xenograft model, the sizes of tumors which were treated with a single agent and with a combination of agents decreased in a time-dependent manner. A combination of TAO and cisplatin resulted in a significantly reduced tumor size (P<0.05). The data for the histochemical staining of TUNEL-positive cells showed that the number of apoptotic cells was significantly increased by the combination of TAO and cisplatin. Thus, TAO is a good candidate for use in a combined regimen with cisplatin for patients with cervical cancer.

View Figures

View References

1	Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D: GLOBOCAN 2008 v2.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer; Lyon: 2010, Available from: http://globocan.iarc.fr.
2	Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar
3	Im SS and Monk BJ: New developments in the treatment of invasive cervical cancer. Obstet Gynecol Clin North Am. 29:659–672. 2002. View Article : Google Scholar : PubMed/NCBI
4	Peters WA III, Liu P, Barrett RJ II, et al: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 18:1606–1613. 2000.
5	Morris M, Eifel PJ, Lu J, et al: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
6	Rose PG, Bundy BN, Watkins EB, et al: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
7	Whitney CW, Sause W, Bundy BN, et al: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 17:1339–1348. 1999.PubMed/NCBI
8	Keys HM, Bundy BN, Stehman FB, et al: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 340:1154–1161. 1999. View Article : Google Scholar : PubMed/NCBI
9	Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L and Major F: Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
10	McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 14:792–795. 1996.PubMed/NCBI
11	Pectasides D, Kamposioras K, Papaxoinis G and Pectasides E: Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 34:603–613. 2008. View Article : Google Scholar : PubMed/NCBI
12	Moore DH, Blessing JA, McQuellon RP, et al: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 22:3113–3119. 2004. View Article : Google Scholar : PubMed/NCBI
13	Monk BJ, Sill MW, McMeekin DS, et al: Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar
14	Wintrobe MM: Clinical Hematology. 3rd edition. Henry Kimpton; London: 1951
15	Kim J, Bae SM, Lim DS, et al: Tetraarsenic oxide-mediated apoptosis in a cervical cancer cell line, SiHa. Cancer Res Treat. 37:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
16	Park SG, Jung JJ, Won HJ, et al: Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect. Cancer Lett. 277:212–217. 2009. View Article : Google Scholar : PubMed/NCBI
17	Chung WH, Sung BH, Kim SS, Rhim H and Kuh HJ: Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro. Int J Oncol. 34:1669–1679. 2009.PubMed/NCBI
18	Benedet JL, Odicino F, Maisonneuve P, et al: Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 83(Suppl 1): 41–78. 2003. View Article : Google Scholar
19	Mandic A, Hansson J, Linder S and Shoshan MC: Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 278:9100–9106. 2003. View Article : Google Scholar : PubMed/NCBI
20	Robati M, Holtz D and Dunton CJ: A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag. 4:213–218. 2008.PubMed/NCBI
21	Bonomi P, Blessing J, Ball H, Hanjani P and DiSaia PJ: A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 34:357–359. 1989. View Article : Google Scholar : PubMed/NCBI
22	Daghestani AN, Hakes TB, Lynch G and Lewis JL: Cervix carcinoma: treatment with combination cisplatin and bleomycin. Gynecol Oncol. 16:334–339. 1983. View Article : Google Scholar : PubMed/NCBI
23	Cervellino JC, Araujo CE, Sánchez O, Miles H and Nishihama A: Cisplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. A phase II trial. Acta Oncol. 34:257–259. 1995. View Article : Google Scholar : PubMed/NCBI
24	Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al: Phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma. Ann Oncol. 12:541–547. 2001. View Article : Google Scholar : PubMed/NCBI
25	Pignata S, Silvestro G, Ferrari E, et al: Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 17:756–760. 1999.PubMed/NCBI
26	Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 17:2676–2680. 1999.
27	Papadimitriou CA, Sarris K, Moulopoulos LA, et al: Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol. 17:761–766. 1999.PubMed/NCBI
28	Piver MS, Ghamande SA, Eltabbakh GH and O’Neill-Coppola C: First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix: a phase II study. Gynecol Oncol. 75:334–337. 1999. View Article : Google Scholar : PubMed/NCBI
29	Fiorica J, Holloway R, Ndubisi B, et al: Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and non-squamous carcinomas of the cervix. Gynecol Oncol. 85:89–94. 2002. View Article : Google Scholar : PubMed/NCBI
30	Zhang N, Wu ZM, McGowan E, et al: Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 100:2459–2464. 2009. View Article : Google Scholar
31	Woo SH, Park MJ, An S, et al: Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF-and VEGF-induced proliferation of human endothelial cells. J Cell Biochem. 95:120–130. 2005. View Article : Google Scholar : PubMed/NCBI
32	Thigpen T, Vance R, Khansur T and Malamud F: The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 24(1 Suppl 2): S2-41–S2-46. 1997.PubMed/NCBI
33	Rowinsky EK, Gilbert M, McGuire W, et al: Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 9:1692–1703. 1991.PubMed/NCBI
34	Delaloge S, Laadem A, Taamma A, et al: Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am J Clin Oncol. 23:569–574. 2000. View Article : Google Scholar : PubMed/NCBI
35	Gordinier M, Kudelka A, Kavanagh J, Wharton J and Freedman R: Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. Int J Gynecol Cancer. 12:710–714. 2002. View Article : Google Scholar : PubMed/NCBI
36	Serova M, Calvo F, Lokiec F, et al: Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells. Cancer Chemother Pharmacol. 57:491–499. 2006. View Article : Google Scholar : PubMed/NCBI